Determination of Insulin-stimulated Hepatic Glucose Uptake by PET-CT Measurements

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

15 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-08-01

Study Completion Date

2023-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In the absence of excessive alcohol consumption, increased levels of fat in the liver (\>5%) are diagnosed as non-alcoholic fatty liver (NAFL). It has been shown that NAFL is strongly associated with impairments in metabolic health such as hepatic and whole-body insulin resistance. Insulin resistance is seen as the earliest hallmark in the development of type 2 diabetes.

Insulin has two main effects on the liver: suppressing endogenous glucose production (EGP) and increasing glucose uptake. While the former has been extensively studied and is known to be impaired in NAFL, no studies have yet examined whether insulin-stimulated hepatic glucose uptake is affected by NAFL.

Recent methodological developments allow us to visualize and quantify glucose uptake in any given tissue using dynamic Positron Emission Tomography (PET) with 18Fluorinated glucose tracer (FDG) during insulin stimulation.

In the present study, we will in a first instance optimize the insulin-stimulated whole-body PET protocol and apply the dose as reported in the literature 4 megabequerels per kg of body weight (MBq/kg) (±8 mSv) in the first three subjects. It will then be evaluated whether the dose can be decreased in the remaining measurements. Another twelve individuals will then undergo the optimized dynamic PET protocol to assess insulin-stimulated hepatic glucose together with whole-body glucose uptake measures. Liver fat content and composition will be assessed by proton magnetic resonance spectroscopy (1H-MRS). Fasted De Novo Lipogenesis (DNL) will also be measured by deuterated water. Additionally, a two-step clamp will be performed to measure whole-body insulin sensitivity and insulin-stimulated suppression of EGP. The identification of the contributing factors to insulin resistance during the development of NAFL is crucial in order to develop more effective strategies for the prevention and treatment of metabolic disorders.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Non-invasive Evaluation of Hepatic Fibrosis in Patients With the Metabolic Syndrome

NCT00399932

Metabolic Syndrome

UNKNOWN

Study of Magnetic Resonance Imaging (MRI) to Quantify Liver Fat in Diabetic and Pre-Diabetic Patients (0000-171)

NCT01110577

Non-alcoholic Fatty Liver Disease (NAFLD)

COMPLETED

NASH: Non-invasive Diagnostic Markers and Imaging

NCT02717000

Nonalcoholic Fatty Liver Disease Nonalcoholic Steatohepatitis

UNKNOWN

Association of Non-alcoholic Fatty Liver Disease and Diabetes Mellitus

NCT01997424

Non-alcoholic Fatty Liver Disease (NAFLD)

COMPLETED NA

Mapping of Metabolic Liver Functions in Patients With Non-alcoholic Fatty Liver Disease

NCT02488941

Non-alcoholic Fatty Liver Disease

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Objective:

To determine the association between insulin-stimulated hepatic glucose uptake measured by dynamic PET and liver fat content in overweight/obese subjects.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

NAFLD Insulin Resistance Overweight and Obesity

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

CROSS_SECTIONAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Caucasian (people will be excluded when having a ≥50% racial African/Asian background)
* Male or postmenopausal female
* Aged 45-75 years at start of the study
* Body mass index (BMI) 27 - 38 kg/m2
* Stable dietary habits (no weight loss or gain \>3kg in the past 3 months)
* Sedentary lifestyle (not more than 2 hours of vigorous exercise per week)

Exclusion Criteria

* Type 2 diabetes (fasted blood glucose \> 7 mmol/L)
* Any condition or medical history that would in the investigator's or dependent physician's opinion interfere with the study, with study outcomes or increase the risk of the study procedures
* Alcohol consumption of \>2 servings per day
* Smoking
* Low Hb (men: \<8.6 mmol/L; women \<7.4 mmol/L)
* Use of medication known to interfere with the safety of study procedures
* Use of medication known to increase liver fat, like for instance corticosteroids (parenteral \& oral chronic administration only), amiodarone (Cordarone), tamoxifen (Nolvadex), and methotrexate (Rheumatrex, Trexall).
* Subjects receiving thiazolidinediones (glitazones \[pioglitazone, rosiglitazone\]).
* Participation in research or medical examination that included PET/CT scanning in the last 3 months
* Contra-indication for MRI

Minimum Eligible Age

45 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes